Hemant Surgical Industries Ltd
Incorporated in 1989, Hemant Surgical Industries Ltd is in the business of Medical Equipment & Supplies[1]
- Market Cap ₹ 526 Cr.
- Current Price ₹ 404
- High / Low ₹ 446 / 90.0
- Stock P/E 28.9
- Book Value ₹ 105
- Dividend Yield 0.00 %
- ROCE 19.6 %
- ROE 18.2 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 68.0% CAGR over last 5 years
- Company's working capital requirements have reduced from 45.5 days to 24.0 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -6.07%
- Debtor days have increased from 83.7 to 106 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| 51 | 56 | 56 | 60 | 101 | 109 | 106 | 107 | 231 | |
| 48 | 53 | 53 | 57 | 95 | 98 | 95 | 97 | 208 | |
| Operating Profit | 2 | 3 | 3 | 3 | 6 | 11 | 10 | 9 | 23 |
| OPM % | 5% | 5% | 5% | 5% | 6% | 10% | 10% | 9% | 10% |
| 0 | 0 | 0 | 1 | 2 | 2 | 4 | 5 | 6 | |
| Interest | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 4 |
| Depreciation | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 2 |
| Profit before tax | 1 | 1 | 1 | 1 | 6 | 10 | 13 | 11 | 24 |
| Tax % | 10% | 8% | 41% | 9% | 25% | 24% | 23% | 23% | 23% |
| 1 | 1 | 0 | 1 | 5 | 8 | 10 | 8 | 18 | |
| EPS in Rs | 50.76 | 61.02 | 27.00 | 73.43 | 248.92 | 9.95 | 9.39 | 7.79 | 13.98 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 31% |
| 3 Years: | 28% |
| TTM: | 117% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 68% |
| 3 Years: | 34% |
| TTM: | 128% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 321% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 18% |
| Last Year: | 18% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 8 | 10 | 10 | 13 |
| Reserves | 5 | 6 | 5 | 8 | 11 | 16 | 44 | 53 | 124 |
| 9 | 11 | 14 | 14 | 10 | 7 | 7 | 31 | 50 | |
| 12 | 14 | 23 | 15 | 32 | 34 | 38 | 54 | 87 | |
| Total Liabilities | 28 | 33 | 44 | 40 | 54 | 65 | 100 | 148 | 274 |
| 7 | 8 | 10 | 11 | 12 | 13 | 18 | 40 | 53 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 0 |
| Investments | 0 | 0 | 1 | 0 | 1 | 0 | 5 | 1 | 0 |
| 21 | 25 | 33 | 29 | 42 | 51 | 77 | 94 | 220 | |
| Total Assets | 28 | 33 | 44 | 40 | 54 | 65 | 100 | 148 | 274 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 2 | -4 | 12 | 6 | -4 | 9 | -32 | |
| 0 | 0 | -2 | -2 | -0 | -3 | -12 | -30 | -3 | |
| 0 | 0 | 2 | 5 | -8 | -1 | 21 | 18 | 69 | |
| Net Cash Flow | 0 | 0 | 2 | -2 | 4 | 3 | 5 | -4 | 34 |
| Free Cash Flow | 0 | 0 | -1 | -7 | 12 | 2 | -13 | -25 | -34 |
| CFO/OP | 0% | 0% | 68% | -127% | 197% | 84% | -9% | 126% | -118% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 35 | 36 | 35 | 26 | 56 | 58 | 75 | 70 | 106 |
| Inventory Days | 64 | 73 | 125 | 113 | 57 | 67 | 99 | 205 | 120 |
| Days Payable | 102 | 97 | 143 | 89 | 92 | 110 | 116 | 188 | 146 |
| Cash Conversion Cycle | -3 | 12 | 17 | 51 | 21 | 15 | 58 | 87 | 80 |
| Working Capital Days | 12 | 23 | -28 | 41 | -19 | 2 | 52 | 61 | 24 |
| ROCE % | 15% | 12% | 14% | 32% | 45% | 30% | 16% | 20% |
Insights
In beta| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Number of Registered Medical Products Count |
|
|||||
| Gross Cash Cycle (GCA Days) Days |
||||||
| Manufacturing Infrastructure Footprint Sq. Ft. |
||||||
| Number of Distributors in India Count |
||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Acquisition
2d - Hemant Surgical to acquire 66.66% of Lifesenz for Rs 19.998 crore by September 30, 2026.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 20 May
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 20 May
-
Announcement under Regulation 30 (LODR)-Allotment
15 May - 14,99,200 equity shares allotted on May 15, 2026 via warrant conversion at ₹197 each.
-
Intimation Of Appointment Of Cost Auditor
15 May - On May 15, 2026, Hemant Surgical appointed M/s K Sorathiya & Co. as cost auditor for FY2026-27.
Business Overview:[1][2]
HSIL is ISO 9001:2015, ISO 13485:2016 certified and CDSCO compliant company which deals in importing, manufacturing, and marketing medical disposable, surgical equipments and pharmaceutical products including
a) Supply of dialysis equipment, renal care, oxygen concentrators, air mattresses, ultrasound machines and digital thermometers, etc.
b) Design and manufacture of a range of nebulisers, which are
marketed under the company’s AERO brand
c) HSIL also refurbishes second-hand dialysis machines, manufactures
and supplies related accessories, dialysers and haemodialysis solutions